Stocks analysis

ABBV vs ACN Stock Comparison

Scores Breakdown

Metric ABBV ACN
📈 Growth 26/30 28/30
💰 Profitability 18/20 16/20
🏦 Financial Health 6/20 18/20
💵 Valuation 12/20 15/20
⚠️ Risk (lower is better) 8/10 5/10
Overall Score 64/100 82/100

Side-by-Side Summaries

ABBV Analysis ACN Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from $17.69B to $18.72B, while Net Income increased from $1.79B to $2.34B, signaling a positive trajectory with modest top-line growth and stronger bottom-line advancement. The trend shows resilience amid quarterly fluctuations, with mid-single-digit revenue growth and improving profitability.

💰 Margins & Cash Flow

Gross Margin sits in the low 30s (about 32%–33%), and Operating Margin runs in the mid-teens, supporting the Net Income growth. Cash flow is robust: Net Cash Flow From Operating Activities around $3.0–3.8B per quarter; Net Cash Flow overall was positive in several periods, while Net Cash Flow From Investing Activities and Net Cash Flow From Financing Activities show volatility.

🛡️ Balance Sheet & Liquidity

Liquidity remains solid with Current Assets around $25–29B versus Current Liabilities around $18–22B (current ratio near 1.3x). Equity sits near $31–33B, and overall liabilities are manageable relative to assets.

⚠️ Key Drivers & Risks

  • Drivers: AI-enabled transformation demand and a broad, diversified client base across industries.
  • Risks: Economic cyclicality in IT budgets and valuation sensitivity to growth assumptions.